Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Cabaletta Bio, Inc.

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in systemic lupus erythematosus and myositis, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.

5AM Ventures

Baker Brothers Advisors LLC

Boxer Capital

Cormorant Capital

Deerfield Capital Management

Penn Medicine Co-Investment Program

Redmile Group

Adage Capital Management

Cabaletta Bio

Cabaletta Bio recognizes and congratulates Georg Schett, innovator and global leader in the use of CD19-targeting cell therapies for patients with autoimmune diseases, along with his team on their landmark publication in the New England Journal of Medicine. Their academic case series study demonstrated durable clinical responses across 15 patients (8 with lupus, 3 with myositis and 4 with systemic sclerosis) treated with a 4-1BB co-stimulatory domain containing autologous CD19-CAR T construct. We believe these published data represent a pivotal moment in the effort to bring potentially transformative treatment to patients with a broad range of autoimmune diseases. #CART #autoimmunity #lupus #myositis #scleroderma https://lnkd.in/eU_KVCwH

Cabaletta Bio is excited to announce that the FDA has granted orphan drug designation to CABA-201 for the treatment of myositis. This designation is an important recognition for investigational therapies in rare diseases as we seek to deliver the first targeted, potentially curative, cell therapy for patients with autoimmune disease. Cabaletta's RESET-Myositis and RESET-SLE trials are currently enrolling patients [https://lnkd.in/eXEnYuh2, https://lnkd.in/eXHmWhbG] #CART #autoimmune #myositis. https://lnkd.in/exzwpp_n


Dr. Gwendolyn Binder PhD, President of Science and Technology at Cabaletta Bio, will be delivering the opening keynote presentation at the 7th annual Cell & Gene Therapy Innovation Summit where she will review the history and current state of art for engineered T cell therapy for patients with autoimmune diseases. Join us in Barcelona on Wednesday, February 7, 2024 in Barcelona for the presentation!

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
average inventory
average payables		396K -	761.50K 92.30%	1.08M 42.02%	1.79M 65.33%	2.40M 34.12%	3.50M 46.16%
average receivables
book value per share		-0.74 -	25.29 3,533.25%	4.73 81.29%	35.44 648.71%	4.85 86.30%	5.77 18.85%
capex per share			-0.13 -	-0.03 78.35%	-0.35 1,176.75%	-0.11 67.48%	-0.02 85.27%
capex to depreciation			-6.66 -	-1.79 73.08%	-1.59 11.32%	-2.08 30.91%	-0.48 76.86%
capex to operating cash flow			0.04 -	0.02 45.08%	0.03 44.11%	0.05 54.72%	0.01 75.74%
capex to revenue
cash per share		2.28 -	24.90 994.58%	4.69 81.15%	36.72 682.08%	4.95 86.52%	5.89 19.08%
days of inventory on hand
days payables outstanding							1.16K -
days sales outstanding
debt to assets						0.04 -	0.02 54.96%
debt to equity						0.05 -	0.02 56.78%
dividend yield			0.13 -
earnings yield		-0.08 -	-0.20 135.03%	-0.11 43.08%	-3.61 3,108.55%	-0.26 92.79%	-0.07 72.01%
enterprise value	-1K -	112.11M 11,210,627%	-59.80M 153.34%	187.42M 413.43%	-109.61M 158.48%	122.72M 211.97%	741.25M 504.00%
enterprise value over ebitda		-18.10 -	3.20 117.68%	-5.54 273.08%	2.37 142.72%	-2.27 195.78%	-10.12 346.51%
ev to operating cash flow		-24.05 -	3.73 115.49%	-7.00 287.86%	3.21 145.90%	-2.65 182.34%	-13.84 423.14%
ev to sales
free cash flow per share		-0.32 -	-3.06 852.84%	-1.18 61.31%	-10.60 794.99%	-2.27 78.60%	-1.32 41.59%
free cash flow yield		-0.03 -	-0.22 582.06%	-0.09 56.69%	-2.80 2,847.09%	-0.25 91.23%	-0.06 76.20%
graham net net		-0.82 -	24.33 3,080.06%	4.47 81.62%	34.20 664.92%	4.37 87.22%	5.47 25.08%
graham number		3.73 -	39.63 961.72%	12.23 69.15%	104.43 754.13%	16.21 84.48%	14.65 9.64%
income quality		0.38 -	0.95 147.91%	0.80 15.21%	0.74 8.23%	0.88 18.81%	0.79 9.62%
intangibles to total assets	0 -	0	0	0	0	0	0
interest coverage						45.96 -
interest debt per share						0.18 -	0.12 33.36%
inventory turnover
invested capital						0.05 -	0.02 56.78%
market cap		145.12M -	76.41M 47.35%	288.85M 278.04%	12.62M 95.63%	199.19M 1,478.89%	929.47M 366.62%
net current asset value	-249K -	-10.87M 4,265.46%	137.41M 1,364.08%	108.36M 21.14%	116.16M 7.20%	96.39M 17.02%	227.04M 135.55%
net debt to ebitda		5.33 -	7.29 36.74%	3.00 58.88%	2.64 11.97%	1.41 46.48%	2.57 81.96%
net income per share		-0.84 -	-2.76 228.33%	-1.40 49.15%	-13.68 874.39%	-2.41 82.41%	-1.65 31.30%
operating cash flow per share		-0.32 -	-2.93 813.39%	-1.16 60.57%	-10.25 785.93%	-2.15 78.98%	-1.31 39.28%
payables turnover							0.31 -
receivables turnover
research and ddevelopement to revenue
return on tangible assets		-0.36 -	-0.11 70.11%	-0.28 165.35%	-0.36 27.26%	-0.44 22.90%	-0.27 39.77%
revenue per share
roe		1.14 -	-0.11 109.56%	-0.30 171.72%	-0.39 30.14%	-0.50 28.42%	-0.29 42.20%
roic		0.57 -	-0.12 121.19%	-0.30 150.06%	-0.39 28.31%	-0.46 19.43%	-0.31 33.30%
sales general and administrative to revenue
shareholders equity per share		-0.74 -	25.29 3,533.25%	4.73 81.29%	35.44 648.71%	4.85 86.30%	5.77 18.85%
stock based compensation to revenue
tangible asset value	-249K -	-10.69M 4,193.17%	138.32M 1,393.93%	109.54M 20.80%	117.96M 7.68%	104.52M 11.39%	236.20M 125.98%
tangible book value per share		-0.74 -	25.29 3,533.25%	4.73 81.29%	35.44 648.71%	4.85 86.30%	5.77 18.85%
working capital	-249K -	33.05M 13,373.49%	137.41M 315.74%	108.36M 21.14%	116.16M 7.20%	99.34M 14.48%	228.50M 130.00%

NASDAQ:CABA

Cabaletta Bio, Inc.

Last Close

12.69

16/05 16:26

Market Cap

954.68M

Beta: 2.53

Volume Today

194.73K

Avg: 390.10K

PE Ratio

−15.75

PFCF: −19.39